Welcome to Morningstar.co.uk!
You have been redirected here from Hemscott.com as we are merging our websites to provide you with a one-stop shop for all your investment research needs.
Get Started: To search for a security, type the name or ticker in the search box at the top of the page and select from the dropdown results.
Registered Hemscott users can log in to Morningstar using the same login details. Similarly, if you are a Hemscott Premium user, you now have a Morningstar Premium account which you can access using the same login details.
AIM WINNERS & LOSERS: Bahamas Petroleum Sinks As Pulls Plug On Well
Mon, 8th Feb 2021 10:46
(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Monday.
AIM - WINNERS
Omega Diagnostics, up 40% at 96.98 pence, 12-month range 5.93p-126.95p. It will continue to modify its Alva-based facility to upscale significantly its lateral flow test production capacity as it noted a Financial Times article. The FT said the UK government has chosen three British companies to make rapid Covid-19 tests. The newspaper said Omega, SureScreen and Global Access Diagnostics have been selected by the Department of Health to produce up to 2 million lateral flow devices per day for the UK, according to two people briefed on the decision.
Follow Oliver on:
A round-up of some of the big share price moves in London on Monday
Yourgene Health PLC (LON:YGEN), the diagnotics group, has sent its shares 8% to 12.05p lower in afternoon trading, with the warning that while trading in the second half was better than the first, full-year sales will be below market estimates.
The company said it made around £4mln from coronavirus testing, including through the UK s Fit to Fly and Test to Release schemes, but this was crimped by restrictions on domestic and international travel.
Along with its network of partners, the company said it was primed for the reopening of the UK economy and international travel markets, with an expanded testing capacity in Manchester facility that is currently only operating at around 25%, around half the volume seen in December, with testing partners experiencing similar volume reductions.